25 XP   0   0   10

Oncternal Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Oncternal together

PenkeI guess you are interested in Oncternal Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Oncternal Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Oncternal Therapeutics Inc

I send you an email if I find something interesting about Oncternal Therapeutics Inc.

Quick analysis of Oncternal (30 sec.)










What can you expect buying and holding a share of Oncternal? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$10.15
Expected worth in 1 year
$-0.29
How sure are you?
25.0%

+ What do you gain per year?

Total Gains per Share
$-10.45
Return On Investment
-122.2%

For what price can you sell your share?

Current Price per Share
$8.55
Expected price per share
$6.68 - $10.40
How sure are you?
50%

1. Valuation of Oncternal (5 min.)




Live pricePrice per Share (EOD)

$8.55

Intrinsic Value Per Share

$-141.50 - $-36.08

Total Value Per Share

$-131.35 - $-25.92

2. Growth of Oncternal (5 min.)




Is Oncternal growing?

Current yearPrevious yearGrowGrow %
How rich?$30m$70.9m-$29.7m-72.2%

How much money is Oncternal making?

Current yearPrevious yearGrowGrow %
Making money-$9.8m-$10.7m$915k9.3%
Net Profit Margin-5,677.0%-3,815.9%--

How much money comes from the company's main activities?

3. Financial Health of Oncternal (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#531 / 1010

Most Revenue
#599 / 1010

Most Profit
#560 / 1010

Most Efficient
#913 / 1010

What can you expect buying and holding a share of Oncternal? (5 min.)

Welcome investor! Oncternal's management wants to use your money to grow the business. In return you get a share of Oncternal.

What can you expect buying and holding a share of Oncternal?

First you should know what it really means to hold a share of Oncternal. And how you can make/lose money.

Speculation

The Price per Share of Oncternal is $8.545. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Oncternal.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Oncternal, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $10.15. Based on the TTM, the Book Value Change Per Share is $-2.61 per quarter. Based on the YOY, the Book Value Change Per Share is $4.70 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Oncternal.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-3.10-36.2%-3.12-36.5%-1.12-13.1%-1.21-14.2%-1.79-21.0%
Usd Book Value Change Per Share-2.35-27.5%-2.61-30.6%4.7055.1%0.131.5%0.161.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-2.35-27.5%-2.61-30.6%4.7055.1%0.131.5%0.161.9%
Usd Price Per Share0.54-0.50-1.10-2.75-3.42-
Price to Earnings Ratio-0.04--0.04--1.02--3.33--1.84-
Price-to-Total Gains Ratio-0.23--0.19--5.12--8.06--4.29-
Price to Book Ratio0.05-0.04-0.59-1.76-1.17-
Price-to-Total Gains Ratio-0.23--0.19--5.12--8.06--4.29-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share8.545
Number of shares117
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-2.610.13
Usd Total Gains Per Share-2.610.13
Gains per Quarter (117 shares)-305.5514.94
Gains per Year (117 shares)-1,222.2159.78
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1222-123206050
20-2444-24540120110
30-3667-36760179170
40-4889-48980239230
50-6111-61200299290
60-7333-73420359350
70-8555-85640418410
80-9778-97860478470
90-11000-110080538530
100-12222-122300598590

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%2.038.00.05.0%4.077.00.04.9%
Book Value Change Per Share0.04.00.00.0%1.011.00.08.3%3.017.00.015.0%10.030.00.025.0%18.063.00.022.2%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%3.00.078.03.7%
Total Gains per Share0.04.00.00.0%1.011.00.08.3%3.017.00.015.0%10.030.00.025.0%18.063.00.022.2%

Fundamentals of Oncternal

About Oncternal Therapeutics Inc

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.

Fundamental data was last updated by Penke on 2024-04-11 16:55:08.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Oncternal Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Oncternal earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Oncternal to the Biotechnology industry mean.
  • A Net Profit Margin of -3,085.5% means that $-30.86 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Oncternal Therapeutics Inc:

  • The MRQ is -3,085.5%. The company is making a huge loss. -2
  • The TTM is -5,677.0%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-3,085.5%TTM-5,677.0%+2,591.5%
TTM-5,677.0%YOY-3,815.9%-1,861.1%
TTM-5,677.0%5Y-2,512.5%-3,164.5%
5Y-2,512.5%10Y-1,517.8%-994.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3,085.5%-200.1%-2,885.4%
TTM-5,677.0%-216.8%-5,460.2%
YOY-3,815.9%-288.3%-3,527.6%
5Y-2,512.5%-449.1%-2,063.4%
10Y-1,517.8%-605.5%-912.3%
1.1.2. Return on Assets

Shows how efficient Oncternal is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Oncternal to the Biotechnology industry mean.
  • -25.0% Return on Assets means that Oncternal generated $-0.25 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Oncternal Therapeutics Inc:

  • The MRQ is -25.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -21.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-25.0%TTM-21.3%-3.7%
TTM-21.3%YOY-13.9%-7.3%
TTM-21.3%5Y-19.3%-2.0%
5Y-19.3%10Y-22.1%+2.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-25.0%-13.3%-11.7%
TTM-21.3%-12.8%-8.5%
YOY-13.9%-11.7%-2.2%
5Y-19.3%-13.9%-5.4%
10Y-22.1%-15.7%-6.4%
1.1.3. Return on Equity

Shows how efficient Oncternal is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Oncternal to the Biotechnology industry mean.
  • -30.5% Return on Equity means Oncternal generated $-0.30 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Oncternal Therapeutics Inc:

  • The MRQ is -30.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -13.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-30.5%TTM-13.1%-17.4%
TTM-13.1%YOY-10.9%-2.2%
TTM-13.1%5Y-16.7%+3.6%
5Y-16.7%10Y-8.9%-7.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-30.5%-16.9%-13.6%
TTM-13.1%-16.1%+3.0%
YOY-10.9%-15.1%+4.2%
5Y-16.7%-19.3%+2.6%
10Y-8.9%-20.2%+11.3%

1.2. Operating Efficiency of Oncternal Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Oncternal is operating .

  • Measures how much profit Oncternal makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Oncternal to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Oncternal Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-5,221.5%+5,221.5%
TTM-5,221.5%YOY-3,969.1%-1,252.4%
TTM-5,221.5%5Y-2,445.0%-2,776.5%
5Y-2,445.0%10Y-1,487.7%-957.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--296.2%+296.2%
TTM-5,221.5%-232.5%-4,989.0%
YOY-3,969.1%-298.2%-3,670.9%
5Y-2,445.0%-492.1%-1,952.9%
10Y-1,487.7%-632.4%-855.3%
1.2.2. Operating Ratio

Measures how efficient Oncternal is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 33.44 means that the operating costs are $33.44 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Oncternal Therapeutics Inc:

  • The MRQ is 33.444. The company is inefficient in keeping operating costs low. -1
  • The TTM is 60.576. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ33.444TTM60.576-27.132
TTM60.576YOY40.429+20.147
TTM60.5765Y26.128+34.448
5Y26.12810Y16.055+10.073
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ33.4443.231+30.213
TTM60.5763.310+57.266
YOY40.4293.890+36.539
5Y26.1285.739+20.389
10Y16.0557.876+8.179

1.3. Liquidity of Oncternal Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Oncternal is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 6.94 means the company has $6.94 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Oncternal Therapeutics Inc:

  • The MRQ is 6.937. The company is very able to pay all its short-term debts. +2
  • The TTM is 9.026. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.937TTM9.026-2.089
TTM9.026YOY11.354-2.328
TTM9.0265Y10.180-1.154
5Y10.18010Y7.232+2.949
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.9373.890+3.047
TTM9.0264.173+4.853
YOY11.3545.344+6.010
5Y10.1806.126+4.054
10Y7.2326.448+0.784
1.3.2. Quick Ratio

Measures if Oncternal is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Oncternal to the Biotechnology industry mean.
  • A Quick Ratio of 12.01 means the company can pay off $12.01 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Oncternal Therapeutics Inc:

  • The MRQ is 12.013. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 14.544. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ12.013TTM14.544-2.531
TTM14.544YOY11.826+2.718
TTM14.5445Y11.208+3.337
5Y11.20810Y8.392+2.816
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ12.0133.514+8.499
TTM14.5443.998+10.546
YOY11.8265.380+6.446
5Y11.2086.105+5.103
10Y8.3926.404+1.988

1.4. Solvency of Oncternal Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Oncternal assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Oncternal to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.18 means that Oncternal assets are financed with 18.2% credit (debt) and the remaining percentage (100% - 18.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Oncternal Therapeutics Inc:

  • The MRQ is 0.182. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.134. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.182TTM0.134+0.048
TTM0.134YOY0.092+0.042
TTM0.1345Y0.168-0.035
5Y0.16810Y0.282-0.113
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1820.339-0.157
TTM0.1340.336-0.202
YOY0.0920.271-0.179
5Y0.1680.366-0.198
10Y0.2820.389-0.107
1.4.2. Debt to Equity Ratio

Measures if Oncternal is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Oncternal to the Biotechnology industry mean.
  • A Debt to Equity ratio of 22.2% means that company has $0.22 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Oncternal Therapeutics Inc:

  • The MRQ is 0.222. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.083. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.222TTM0.083+0.139
TTM0.083YOY0.070+0.013
TTM0.0835Y0.197-0.114
5Y0.19710Y0.890-0.692
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2220.388-0.166
TTM0.0830.402-0.319
YOY0.0700.335-0.265
5Y0.1970.426-0.229
10Y0.8900.461+0.429

2. Market Valuation of Oncternal Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Oncternal generates.

  • Above 15 is considered overpriced but always compare Oncternal to the Biotechnology industry mean.
  • A PE ratio of -0.04 means the investor is paying $-0.04 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Oncternal Therapeutics Inc:

  • The EOD is -0.690. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.044. Based on the earnings, the company is expensive. -2
  • The TTM is -0.040. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.690MRQ-0.044-0.646
MRQ-0.044TTM-0.040-0.004
TTM-0.040YOY-1.017+0.977
TTM-0.0405Y-3.329+3.289
5Y-3.32910Y-1.835-1.493
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.690-2.264+1.574
MRQ-0.044-2.629+2.585
TTM-0.040-2.680+2.640
YOY-1.017-4.145+3.128
5Y-3.329-6.257+2.928
10Y-1.835-6.254+4.419
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Oncternal Therapeutics Inc:

  • The EOD is -0.985. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.062. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.046. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.985MRQ-0.062-0.923
MRQ-0.062TTM-0.046-0.016
TTM-0.046YOY-1.259+1.213
TTM-0.0465Y-3.654+3.608
5Y-3.65410Y-2.051-1.603
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.985-2.973+1.988
MRQ-0.062-3.333+3.271
TTM-0.046-3.553+3.507
YOY-1.259-5.605+4.346
5Y-3.654-8.376+4.722
10Y-2.051-8.865+6.814
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Oncternal is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.05 means the investor is paying $0.05 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Oncternal Therapeutics Inc:

  • The EOD is 0.842. Based on the equity, the company is cheap. +2
  • The MRQ is 0.053. Based on the equity, the company is cheap. +2
  • The TTM is 0.036. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.842MRQ0.053+0.788
MRQ0.053TTM0.036+0.017
TTM0.036YOY0.590-0.554
TTM0.0365Y1.762-1.725
5Y1.76210Y1.175+0.587
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.8421.896-1.054
MRQ0.0532.115-2.062
TTM0.0362.093-2.057
YOY0.5902.884-2.294
5Y1.7623.542-1.780
10Y1.1753.916-2.741
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Oncternal Therapeutics Inc.

3.1. Institutions holding Oncternal Therapeutics Inc

Institutions are holding 16.125% of the shares of Oncternal Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Vanguard Group Inc4.83320286090600
2023-12-31Millennium Management LLC3.47320.0005205590440866024.8087
2023-12-31BlackRock Inc1.3273078568100
2023-12-31Pasadena Private Wealth, LLC0.84470.065450000022125079.3722
2023-12-31Richmond Brothers Inc0.83460.461849404200
2023-12-31Renaissance Technologies Corp0.55280.0003327200139004.4366
2023-12-31LPL Financial Corp0.28970.000117145900
2023-12-31State Street Corporation0.2727016140100
2023-12-31IEQ CAPITAL, LLC0.2440.001314443400
2023-12-31Morgan Stanley - Brokerage Accounts0.1571092980-5000-5.1031
2023-12-31Northern Trust Corp0.143108470600
2023-12-31Two Sigma Advisers, LLC0.14120.000183600-14800-15.0407
2023-12-31Two Sigma Investments LLC0.12620.00017468100
2023-12-31Acadian Asset Management LLC0.12290.00027277500
2023-12-31Axxcess Wealth Management, LLC0.11890.00117036300
2023-12-31TWO SIGMA SECURITIES, LLC0.09930.00035876137537176.8611
2023-12-31Regents Of The University Of California0.09050.00365355400
2023-12-31Balboa Wealth Partners0.08020.00854750000
2023-12-31Creative Planning Inc0.066403931800
2023-12-31Charles Schwab Investment Management Inc0.054503224900
Total 13.87250.54338211514+661547+8.1%

3.2. Funds holding Oncternal Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30BlackRock Extended Mkt Composite0.21750.000312871600
2024-02-29Vanguard Total Stock Mkt Idx Inv3.64870.000110798900
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.06810.00034028600
2023-12-31NT Ext Equity Mkt Idx Fd - L0.06580.00043895300
2023-12-31Northern Trust Extended Eq Market Idx0.06580.00043895300
2023-10-31Vanguard Instl Ttl Stck Mkt Idx Tr0.0575034025-2125772-98.4246
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.05470.000332355610.1889
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.04950.00033106100
2023-12-31SSgA U.S. Extended Market Index Class I0.03010.00041783500
2024-03-29Dimensional US Targeted Value ETF0.48670.00131440400
2024-02-29Fidelity Extended Market Index0.4670.000313822-67-0.4824
2024-03-29Dimensional US Small Cap ETF0.29950.001886400
2024-03-31BlackRock Extended Equity Market K0.18980.0004561610.0178
2023-12-31SSgA U.S. Total Market Index Strategy0.00870.00015144-119-2.2611
2023-09-30Blackstone Alternative Multi-Strategy I0.007804600-200-4.1667
2023-12-31Northern Trust Wilshire 50000.00740.0001437900
2023-12-31NT US Market Cap Idx Fd - L0.00740.0001437900
2024-02-29Fidelity Total Market Index0.13610402700
2024-02-29Fidelity Series Total Market Index0.11160.0001330400
2024-03-29Dimensional US Core Equity 2 ETF0.08870.0001262400
Total 7.06840.006541336-2126096-392.7%

3.3. Insider Transactions

Insiders are holding 8.645% of the shares of Oncternal Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-04-08Robert James WillsBUY30868.96
2024-03-28Robert James WillsBUY69148.48
2024-02-23David F HaleBUY7149.04
2023-06-14Gunnar F KaufmannBUY1507.2
2023-06-12Gunnar F KaufmannBUY12507
2023-04-14Salim YazjiBUY2506
2023-04-13James B BreitmeyerBUY50005.8
2023-04-13Richard G VincentBUY15006
2023-04-12Chase C LeavittBUY7505.8
2023-04-12Salim YazjiBUY5005.6

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Oncternal Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---2.346-2.612+11%4.704-150%0.128-1937%0.164-1534%
Book Value Per Share--10.15413.914-27%6.241+63%5.303+91%5.591+82%
Current Ratio--6.9379.026-23%11.354-39%10.180-32%7.232-4%
Debt To Asset Ratio--0.1820.134+36%0.092+99%0.168+8%0.282-36%
Debt To Equity Ratio--0.2220.083+167%0.070+219%0.197+13%0.890-75%
Dividend Per Share----0%-0%-0%-0%
Eps---3.096-3.122+1%-1.123-64%-1.211-61%-1.792-42%
Free Cash Flow Per Share---2.169-2.717+25%-0.895-59%-0.943-57%-1.552-28%
Free Cash Flow To Equity Per Share---2.169-2.627+21%-0.669-69%-0.670-69%0.333-752%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---36.078--------
Intrinsic Value_10Y_min---141.502--------
Intrinsic Value_1Y_max---4.802--------
Intrinsic Value_1Y_min---7.609--------
Intrinsic Value_3Y_max---13.524--------
Intrinsic Value_3Y_min---28.688--------
Intrinsic Value_5Y_max---21.155--------
Intrinsic Value_5Y_min---55.991--------
Market Cap25290123.800+94%1598205.6001465021.800+9%43871417.500-96%79918098.800-98%46300435.243-97%
Net Profit Margin---30.855-56.770+84%-38.159+24%-25.125-19%-15.178-51%
Operating Margin----52.2150%-39.6910%-24.4500%-14.8770%
Operating Ratio--33.44460.576-45%40.429-17%26.128+28%16.055+108%
Pb Ratio0.842+94%0.0530.036+47%0.590-91%1.762-97%1.175-95%
Pe Ratio-0.690-1482%-0.044-0.040-8%-1.017+2232%-3.329+7535%-1.835+4109%
Price Per Share8.545+94%0.5400.495+9%1.098-51%2.753-80%3.423-84%
Price To Free Cash Flow Ratio-0.985-1482%-0.062-0.046-26%-1.259+1922%-3.654+5771%-2.051+3195%
Price To Total Gains Ratio-3.642-1482%-0.230-0.189-18%-5.117+2123%-8.057+3401%-4.290+1764%
Quick Ratio--12.01314.544-17%11.826+2%11.208+7%8.392+43%
Return On Assets---0.250-0.213-15%-0.139-44%-0.193-23%-0.221-11%
Return On Equity---0.305-0.131-57%-0.109-64%-0.167-45%-0.089-71%
Total Gains Per Share---2.346-2.612+11%4.704-150%0.128-1937%0.164-1534%
Usd Book Value--30052000.00041180000.000-27%70927000.000-58%53335250.000-44%35746200.000-16%
Usd Book Value Change Per Share---2.346-2.612+11%4.704-150%0.128-1937%0.164-1534%
Usd Book Value Per Share--10.15413.914-27%6.241+63%5.303+91%5.591+82%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---3.096-3.122+1%-1.123-64%-1.211-61%-1.792-42%
Usd Free Cash Flow---6419000.000-8041000.000+25%-9176000.000+43%-6484900.000+1%-6554525.000+2%
Usd Free Cash Flow Per Share---2.169-2.717+25%-0.895-59%-0.943-57%-1.552-28%
Usd Free Cash Flow To Equity Per Share---2.169-2.627+21%-0.669-69%-0.670-69%0.333-752%
Usd Market Cap25290123.800+94%1598205.6001465021.800+9%43871417.500-96%79918098.800-98%46300435.243-97%
Usd Price Per Share8.545+94%0.5400.495+9%1.098-51%2.753-80%3.423-84%
Usd Profit---9164000.000-9867750.000+8%-10782750.000+18%-8442850.000-8%-7838800.000-14%
Usd Revenue--297000.000196250.000+51%186000.000+60%582100.000-49%279375.000+6%
Usd Total Gains Per Share---2.346-2.612+11%4.704-150%0.128-1937%0.164-1534%
 EOD+5 -3MRQTTM+20 -12YOY+11 -215Y+7 -2510Y+10 -22

4.2. Fundamental Score

Let's check the fundamental score of Oncternal Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.690
Price to Book Ratio (EOD)Between0-10.842
Net Profit Margin (MRQ)Greater than0-30.855
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than112.013
Current Ratio (MRQ)Greater than16.937
Debt to Asset Ratio (MRQ)Less than10.182
Debt to Equity Ratio (MRQ)Less than10.222
Return on Equity (MRQ)Greater than0.15-0.305
Return on Assets (MRQ)Greater than0.05-0.250
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of Oncternal Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.962
Ma 20Greater thanMa 508.832
Ma 50Greater thanMa 1008.884
Ma 100Greater thanMa 2008.810
OpenGreater thanClose8.780
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets36,729
Total Liabilities6,677
Total Stockholder Equity30,052
 As reported
Total Liabilities 6,677
Total Stockholder Equity+ 30,052
Total Assets = 36,729

Assets

Total Assets36,729
Total Current Assets36,059
Long-term Assets670
Total Current Assets
Cash And Cash Equivalents 6,697
Short-term Investments 27,558
Net Receivables 632
Other Current Assets 1,172
Total Current Assets  (as reported)36,059
Total Current Assets  (calculated)36,059
+/-0
Long-term Assets
Property Plant Equipment 258
Long-term Assets Other 412
Long-term Assets  (as reported)670
Long-term Assets  (calculated)670
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities5,198
Long-term Liabilities1,479
Total Stockholder Equity30,052
Total Current Liabilities
Short-term Debt 173
Accounts payable 1,148
Other Current Liabilities 3,877
Total Current Liabilities  (as reported)5,198
Total Current Liabilities  (calculated)5,198
+/-0
Long-term Liabilities
Capital Lease Obligations 318
Long-term Liabilities  (as reported)1,479
Long-term Liabilities  (calculated)318
+/- 1,161
Total Stockholder Equity
Common Stock3
Retained Earnings -197,779
Accumulated Other Comprehensive Income 3
Other Stockholders Equity 227,825
Total Stockholder Equity (as reported)30,052
Total Stockholder Equity (calculated)30,052
+/-0
Other
Capital Stock3
Cash and Short Term Investments 34,255
Common Stock Shares Outstanding 2,948
Liabilities and Stockholders Equity 36,729
Net Debt -6,379
Net Invested Capital 30,052
Net Working Capital 30,861
Property Plant and Equipment Gross 258
Short Long Term Debt Total 318



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-31
> Total Assets 
0
0
0
17,310
89,322
85,042
79,155
73,082
65,671
57,726
47,694
82,811
74,712
63,921
81,728
129,255
121,901
112,735
100,647
159,730
147,076
129,584
116,000
108,109
92,666
79,528
65,057
57,721
52,865
39,778
31,078
64,250
53,862
94,827
86,908
78,184
67,611
59,145
72,168
57,774
44,698
33,491
22,492
15,605
29,793
19,135
13,016
50,651
45,782
41,860
37,778
32,031
26,704
21,977
15,749
24,502
18,943
13,667
55,849
46,236
34,359
47,716
40,269
31,321
22,636
30,903
25,049
21,744
17,765
18,899
23,552
118,809
114,057
108,419
100,296
93,585
85,488
81,526
76,170
68,651
58,282
50,773
43,195
36,729
36,72943,19550,77358,28268,65176,17081,52685,48893,585100,296108,419114,057118,80923,55218,89917,76521,74425,04930,90322,63631,32140,26947,71634,35946,23655,84913,66718,94324,50215,74921,97726,70432,03137,77841,86045,78250,65113,01619,13529,79315,60522,49233,49144,69857,77472,16859,14567,61178,18486,90894,82753,86264,25031,07839,77852,86557,72165,05779,52892,666108,109116,000129,584147,076159,730100,647112,735121,901129,25581,72863,92174,71282,81147,69457,72665,67173,08279,15585,04289,32217,310000
   > Total Current Assets 
0
0
0
15,024
88,523
83,372
77,284
66,152
58,486
49,900
40,480
76,004
67,946
57,413
74,136
121,700
114,536
105,210
93,734
152,264
139,155
120,573
107,650
100,024
84,948
72,076
57,580
50,675
46,174
35,183
26,853
60,360
51,875
93,080
85,342
76,848
66,523
58,165
71,342
56,815
43,596
32,644
21,788
15,171
29,055
18,452
12,461
50,151
45,343
41,290
36,918
31,889
26,558
21,836
15,534
24,298
18,751
13,486
55,680
46,077
34,211
47,580
40,144
31,208
22,534
29,871
24,055
20,787
16,564
18,016
22,707
118,003
113,084
107,599
99,520
92,853
85,066
80,980
74,790
67,290
57,917
50,075
42,492
36,059
36,05942,49250,07557,91767,29074,79080,98085,06692,85399,520107,599113,084118,00322,70718,01616,56420,78724,05529,87122,53431,20840,14447,58034,21146,07755,68013,48618,75124,29815,53421,83626,55831,88936,91841,29045,34350,15112,46118,45229,05515,17121,78832,64443,59656,81571,34258,16566,52376,84885,34293,08051,87560,36026,85335,18346,17450,67557,58072,07684,948100,024107,650120,573139,155152,26493,734105,210114,536121,70074,13657,41367,94676,00440,48049,90058,48666,15277,28483,37288,52315,024000
       Cash And Cash Equivalents 
0
0
0
14,769
80,620
81,444
76,095
64,528
55,578
48,082
37,808
74,014
65,277
55,561
44,551
119,550
111,431
102,028
90,944
100,178
128,313
112,937
101,784
95,510
80,174
67,498
47,457
40,219
29,581
19,990
17,550
58,181
42,790
82,421
73,296
63,745
55,909
47,319
38,731
48,044
36,136
28,252
19,283
14,529
22,432
11,178
9,627
17,880
14,163
14,323
11,797
14,056
12,063
9,572
8,238
8,910
7,771
5,156
53,431
15,816
14,958
16,511
23,089
28,258
21,012
28,516
23,096
20,051
16,019
16,617
21,259
116,737
111,211
103,663
97,380
90,765
82,159
78,900
70,628
37,142
11,244
15,832
14,925
6,697
6,69714,92515,83211,24437,14270,62878,90082,15990,76597,380103,663111,211116,73721,25916,61716,01920,05123,09628,51621,01228,25823,08916,51114,95815,81653,4315,1567,7718,9108,2389,57212,06314,05611,79714,32314,16317,8809,62711,17822,43214,52919,28328,25236,13648,04438,73147,31955,90963,74573,29682,42142,79058,18117,55019,99029,58140,21947,45767,49880,17495,510101,784112,937128,313100,17890,944102,028111,431119,55044,55155,56165,27774,01437,80848,08255,57864,52876,09581,44480,62014,769000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,810
6,389
5,040
3,499
2,157
1,553
1,413
8,085
8,825
9,109
8,374
2,165
450
6,575
8,535
9,715
10,695
8,045
8,610
8,555
8,045
6,085
3,390
1,675
200
5,345
6,080
1,915
31,415
30,437
25,111
22,663
15,200
12,200
10,200
5,200
12,959
8,740
6,200
200
28,083
17,186
29,205
14,984
200
175
0
0
0
0
0
0
0
0
0
0
0
0
0
0
26,582
43,073
29,671
25,380
27,558
27,55825,38029,67143,07326,5820000000000000017520014,98429,20517,18628,0832006,2008,74012,9595,20010,20012,20015,20022,66325,11130,43731,4151,9156,0805,3452001,6753,3906,0858,0458,5558,6108,04510,6959,7158,5356,5754502,1658,3749,1098,8258,0851,4131,5532,1573,4995,0406,3899,8100000000000000000000
       Net Receivables 
0
0
0
0
6,782
825
94
0
0
0
0
153
68
63
28,019
61
68
107
124
40,836
2,462
906
974
1,264
1,192
1,327
373
595
519
369
509
683
680
904
830
981
925
908
22,823
9
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
143
1,100
38
226
178
100
262
186
632
632186262100178226381,10014300000000000000000000000000000000000922,8239089259818309046806835093695195953731,3271,1921,2649749062,46240,836124107686128,01963681530000948256,7820000
       Other Current Assets 
0
0
0
61
1,052
997
989
1,176
2,314
1,577
2,497
1,702
2,430
1,575
1,330
1,882
2,857
2,933
2,557
1,362
1,945
1,515
1,257
1,001
1,970
1,723
1,514
920
6,899
6,326
6,410
875
1,666
1,077
1,351
1,266
1,498
1,223
1,233
717
1,375
1,002
830
442
1,278
1,194
919
856
743
1,856
2,458
2,633
2,295
2,064
2,096
2,429
2,240
2,130
2,049
2,178
2,067
1,864
2,071
2,750
1,347
1,355
959
736
545
1,399
1,448
1,266
1,873
3,936
2,140
2,088
2,907
2,080
4,162
3,285
3,600
4,572
2,187
1,172
1,1722,1874,5723,6003,2854,1622,0802,9072,0882,1403,9361,8731,2661,4481,3995457369591,3551,3472,7502,0711,8642,0672,1782,0492,1302,2402,4292,0962,0642,2952,6332,4581,8567438569191,1941,2784428301,0021,3757171,2331,2231,4981,2661,3511,0771,6668756,4106,3266,8999201,5141,7231,9701,0011,2571,5151,9451,3622,5572,9332,8571,8821,3301,5752,4301,7022,4971,5772,3141,1769899971,05261000
   > Long-term Assets 
0
0
0
2,286
799
1,670
1,871
6,930
7,185
7,826
7,214
6,807
6,766
6,508
7,592
7,555
7,365
7,525
6,913
7,466
7,921
9,011
8,350
8,085
7,718
7,452
7,477
7,046
6,691
4,595
4,225
3,890
1,987
1,747
1,566
1,336
1,088
980
826
959
1,102
847
704
434
738
683
555
500
439
570
860
142
146
141
215
204
192
181
169
159
148
136
125
113
102
1,032
994
957
1,201
883
845
806
973
820
776
732
422
546
1,380
1,361
365
698
703
670
6707036983651,3611,3805464227327768209738068458831,2019579941,0321021131251361481591691811922042151411461428605704395005556837384347048471,1029598269801,0881,3361,5661,7471,9873,8904,2254,5956,6917,0467,4777,4527,7188,0858,3509,0117,9217,4666,9137,5257,3657,5557,5926,5086,7666,8077,2147,8267,1856,9301,8711,6707992,286000
       Property Plant Equipment 
0
0
0
815
799
1,439
1,523
1,537
1,612
1,843
1,865
1,746
1,790
1,665
1,556
1,448
1,394
1,638
1,506
2,308
2,787
3,967
4,164
3,988
3,708
3,528
3,638
3,291
3,021
2,680
2,347
2,040
1,764
1,526
1,302
1,096
890
779
640
507
389
285
217
112
86
58
42
29
16
12
8
5
12
11
89
81
73
65
57
51
43
35
28
19
12
265
226
190
154
117
79
40
204
162
119
75
31
157
122
87
50
366
291
258
25829136650871221573175119162204407911715419022626512192835435157657381891112581216294258861122172853895076407798901,0961,3021,5261,7642,0402,3472,6803,0213,2913,6383,5283,7083,9884,1643,9672,7872,3081,5061,6381,3941,4481,5561,6651,7901,7461,8651,8431,6121,5371,5231,439799815000
       Intangible Assets 
0
0
0
0
0
0
0
4,943
4,901
5,027
5,037
4,978
4,921
4,804
4,810
4,714
4,649
4,538
4,697
4,430
4,346
4,262
4,177
4,093
4,010
3,924
3,839
3,755
3,670
1,915
1,878
1,850
223
221
264
1,850
198
201
186
452
713
562
487
322
652
625
513
471
423
558
852
137
134
130
126
123
119
116
112
108
105
101
97
94
90
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000009094971011051081121161191231261301341378525584234715136256523224875627134521862011981,8502642212231,8501,8781,9153,6703,7553,8393,9244,0104,0934,1774,2624,3464,4304,6974,5384,6494,7144,8104,8044,9214,9785,0375,0274,9014,9430000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,100
767
768
767
1,047
766
766
806
769
658
657
657
391
389
1,258
1,274
0
332
0
0
0033201,2741,2583893916576576587698067667661,0477677687672,1000000000000000000000000000000000000000000000000000000000000000000
> Total Liabilities 
0
0
0
167,541
9,467
9,522
8,576
9,173
10,570
12,454
12,189
9,232
10,708
9,493
37,827
32,206
32,079
31,580
28,780
80,813
79,990
74,468
71,419
76,091
70,829
67,832
65,033
66,471
15,562
14,337
13,093
12,523
3,480
5,121
5,436
6,310
5,843
7,456
12,263
10,073
8,637
8,735
5,554
4,921
4,708
3,850
2,400
32,822
29,887
73,168
33,466
30,172
3,019
3,530
3,364
4,611
4,757
5,185
9,279
7,975
9,610
7,877
9,305
5,210
1,819
7,967
6,899
7,432
7,370
9,301
7,852
5,858
5,754
5,900
5,820
5,465
5,294
7,525
7,626
7,682
5,794
5,589
6,199
6,677
6,6776,1995,5895,7947,6827,6267,5255,2945,4655,8205,9005,7545,8587,8529,3017,3707,4326,8997,9671,8195,2109,3057,8779,6107,9759,2795,1854,7574,6113,3643,5303,01930,17233,46673,16829,88732,8222,4003,8504,7084,9215,5548,7358,63710,07312,2637,4565,8436,3105,4365,1213,48012,52313,09314,33715,56266,47165,03367,83270,82976,09171,41974,46879,99080,81328,78031,58032,07932,20637,8279,49310,7089,23212,18912,45410,5709,1738,5769,5229,467167,541000
   > Total Current Liabilities 
0
0
0
2,249
4,169
4,559
3,948
4,854
6,587
8,807
8,877
5,974
7,695
6,849
12,520
10,337
11,692
12,676
11,360
19,332
21,262
18,495
18,199
20,977
18,586
18,359
18,425
15,952
9,572
6,345
5,493
5,305
3,234
4,904
5,196
6,076
5,608
7,194
11,477
9,495
8,149
8,299
5,165
4,567
4,513
3,703
2,318
32,792
29,867
73,168
33,466
30,172
3,019
3,530
3,364
4,611
4,757
5,185
9,279
7,975
9,610
7,877
9,305
5,210
1,819
7,841
6,770
7,341
7,317
9,000
7,551
5,858
5,723
5,900
5,820
5,465
5,294
7,512
7,626
7,682
5,488
4,831
5,152
5,198
5,1985,1524,8315,4887,6827,6267,5125,2945,4655,8205,9005,7235,8587,5519,0007,3177,3416,7707,8411,8195,2109,3057,8779,6107,9759,2795,1854,7574,6113,3643,5303,01930,17233,46673,16829,86732,7922,3183,7034,5134,5675,1658,2998,1499,49511,4777,1945,6086,0765,1964,9043,2345,3055,4936,3459,57215,95218,42518,35918,58620,97718,19918,49521,26219,33211,36012,67611,69210,33712,5206,8497,6955,9748,8778,8076,5874,8543,9484,5594,1692,249000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-5,852
0
0
0
0
0
6,079
0
0
0
0
0
0
0
0
0
0
0
0
0
-1,345
0
0
0
7
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
139
96
99
101
117
79
40
173
162
119
75
31
144
122
87
50
145
151
173
173151145508712214431751191621734079117101999613900000000000000000000000007000-1,34500000000000006,07900000-5,852000000000000000
       Accounts payable 
0
0
0
461
1,098
1,178
1,193
900
2,049
2,875
1,955
1,407
1,967
990
1,344
1,336
1,748
3,364
1,312
1,614
3,650
1,483
1,329
2,821
1,610
1,499
856
1,268
826
851
1,153
848
658
1,139
829
1,219
937
1,462
1,214
1,707
1,100
1,796
1,253
808
619
992
179
512
438
797
184
382
903
1,387
1,223
1,220
514
603
2,451
2,604
1,739
1,473
3,121
3,279
609
2,765
1,231
871
1,376
1,469
977
1,143
1,892
1,009
2,746
1,959
2,395
2,519
2,456
2,917
1,964
2,224
2,133
1,148
1,1482,1332,2241,9642,9172,4562,5192,3951,9592,7461,0091,8921,1439771,4691,3768711,2312,7656093,2793,1211,4731,7392,6042,4516035141,2201,2231,3879033821847974385121799926198081,2531,7961,1001,7071,2141,4629371,2198291,1396588481,1538518261,2688561,4991,6102,8211,3291,4833,6501,6141,3123,3641,7481,3361,3449901,9671,4071,9552,8752,0499001,1931,1781,098461000
       Other Current Liabilities 
0
0
0
1,788
1,734
2,043
1,417
2,617
3,201
4,595
5,585
3,230
4,391
4,522
3,987
9,001
4,092
3,460
4,196
6,784
6,678
-1
5,936
6,666
5,486
5,338
6,047
4,730
5,055
4,150
2,996
3,112
2,576
3,765
4,367
4,857
4,671
5,732
10,263
7,788
7,049
6,503
3,912
3,759
3,894
2,711
2,139
32,280
29,429
72,371
33,282
29,790
2,116
2,143
2,141
3,391
4,243
4,582
6,828
5,371
7,871
6,404
6,184
1,931
1,210
2,550
2,435
2,731
2,778
3,607
3,273
3,042
2,773
2,493
2,797
3,506
2,868
4,638
4,930
4,678
3,474
2,462
2,868
3,877
3,8772,8682,4623,4744,6784,9304,6382,8683,5062,7972,4932,7733,0423,2733,6072,7782,7312,4352,5501,2101,9316,1846,4047,8715,3716,8284,5824,2433,3912,1412,1432,11629,79033,28272,37129,42932,2802,1392,7113,8943,7593,9126,5037,0497,78810,2635,7324,6714,8574,3673,7652,5763,1122,9964,1505,0554,7306,0475,3385,4866,6665,936-16,6786,7844,1963,4604,0929,0013,9874,5224,3913,2305,5854,5953,2012,6171,4172,0431,7341,788000
   > Long-term Liabilities 
0
0
0
165,292
5,298
4,963
4,628
4,319
3,983
3,647
3,312
3,258
3,013
2,644
25,307
21,869
20,387
18,904
17,420
61,481
58,728
55,973
53,220
55,114
52,243
49,473
46,608
50,519
5,990
7,992
7,600
7,218
246
217
240
234
235
262
786
578
488
436
389
354
195
147
82
30
20
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
126
129
91
53
301
301
0
31
0
0
1,959
2,426
13
2,696
3,004
306
758
1,047
1,479
1,4791,0477583063,0042,696132,4261,95900310301301539112912600000000000000002030821471953543894364885787862622352342402172467,2187,6007,9925,99050,51946,60849,47352,24355,11453,22055,97358,72861,48117,42018,90420,38721,86925,3072,6443,0133,2583,3123,6473,9834,3194,6284,9635,298165,292000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
301
301
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000301301000000000000000000000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
537
0
0
00537000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,347
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000001,3470000000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
0
0
0
-150,231
79,855
75,520
70,579
63,909
55,101
45,272
35,505
73,579
64,004
54,428
43,901
97,049
89,822
81,155
71,867
78,917
67,086
55,116
44,581
32,018
21,837
11,696
24
-8,750
37,303
25,441
17,985
51,727
50,382
89,706
81,472
71,874
61,768
51,689
59,905
47,701
36,061
24,756
16,938
10,684
25,085
15,285
10,616
17,829
15,895
-31,308
4,312
1,859
23,685
18,447
12,385
19,891
14,186
8,482
46,570
38,261
24,749
39,839
30,964
26,111
20,817
-56,524
18,150
14,312
10,395
9,598
15,700
-82,797
108,303
102,519
94,476
-114,130
80,194
74,001
68,544
-158,300
52,488
-178,753
-188,615
30,052
30,052-188,615-178,75352,488-158,30068,54474,00180,194-114,13094,476102,519108,303-82,79715,7009,59810,39514,31218,150-56,52420,81726,11130,96439,83924,74938,26146,5708,48214,18619,89112,38518,44723,6851,8594,312-31,30815,89517,82910,61615,28525,08510,68416,93824,75636,06147,70159,90551,68961,76871,87481,47289,70650,38251,72717,98525,44137,303-8,7502411,69621,83732,01844,58155,11667,08678,91771,86781,15589,82297,04943,90154,42864,00473,57935,50545,27255,10163,90970,57975,52079,855-150,231000
   Common Stock
0
0
0
8
25
25
25
25
25
25
25
31
31
31
31
35
35
35
35
36
36
36
36
36
36
36
36
36
36
37
37
52
52
63
63
63
63
63
63
63
63
63
63
63
75
76
76
140
140
140
140
141
142
142
142
16
16
16
22
22
23
24
24
24
24
15
15
15
15
17
22
49
49
49
49
49
49
52
56
57
59
59
59
3
359595957565249494949494922171515151524242424232222161616142142142141140140140140767675636363636363636363636352523737363636363636363636363535353531313131252525252525258000
   Retained Earnings Total Equity0000-158,3000000-106,057-96,427-88,745-82,797-80,240-75,845-70,310-65,572-61,416-56,524-605,857-600,055-594,640-585,209-575,194-561,637-552,360-543,856-537,451-531,198-524,334-517,420-511,368-513,474-510,241-545,107-497,155-494,771-480,226-475,291-464,347-455,360-447,570-438,633-425,831-413,249-400,231-407,635-397,254-386,174-375,492-366,148000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
-3,505
-3,255
-3,071
-2,886
-2,701
-2,516
-2,286
-1,884
-1,725
-2,043
-2,043
-2,043
-2,679
-2,679
-2,679
-2,679
-3,841
-3,841
-3,841
-3,841
-5,066
-5,066
0
0
-6,492
0
0
0
-7,140
0
0
0
-8,108
0
0
0
-8,761
0
0
0
-3,666
0
0
0
-3,747
-3,747
0
0
-2,849
-2,849
0
0
-2,636
-2,636
0
0
-2,667
-2,667
0
0
-2,625
-2,625
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9
11
-6
0
3
30-611900000000000000-2,625-2,62500-2,667-2,66700-2,636-2,63600-2,849-2,84900-3,747-3,747000-3,666000-8,761000-8,108000-7,140000-6,49200-5,066-5,066-3,841-3,841-3,841-3,841-2,679-2,679-2,679-2,679-2,043-2,043-2,043-1,725-1,884-2,286-2,516-2,701-2,886-3,071-3,255-3,505000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
455,791
456,901
457,985
458,959
459,261
460,073
460,887
461,829
463,326
464,445
465,981
489,357
490,500
490,766
512,460
512,910
513,659
514,413
515,192
534,911
535,725
536,577
551,073
551,621
552,322
598,908
599,876
599,920
625,024
625,580
626,142
626,650
79,445
79,551
79,869
80,690
85,426
95,918
195,699
196,999
198,897
200,484
0
0
0
0
219,203
0
0
0
0
0000219,2030000200,484198,897196,999195,69995,91885,42680,69079,86979,55179,445626,650626,142625,580625,024599,920599,876598,908552,322551,621551,073536,577535,725534,911515,192514,413513,659512,910512,460490,766490,500489,357465,981464,445463,326461,829460,887460,073459,261458,959457,985456,901455,791000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
2,527
221,747
221,931
222,116
222,759
223,031
223,222
223,398
269,860
270,209
270,617
270,979
329,472
330,369
330,905
331,859
352,860
353,772
355,045
356,436
358,966
355,020
356,139
357,287
365,880
361,102
362,180
363,299
411,695
405,805
455,791
456,901
466,093
458,959
459,261
460,073
469,648
461,829
463,326
464,445
469,647
489,357
490,500
490,766
516,207
512,910
513,659
514,413
518,041
534,911
535,725
536,577
553,709
551,621
552,322
598,908
602,543
599,920
625,024
625,580
628,767
626,650
-15
79,551
79,869
80,690
85,426
95,918
-49
196,999
198,897
200,484
-49
204,179
209,724
215,388
-66
222,205
-53
-59
227,825
227,825-59-53222,205-66215,388209,724204,179-49200,484198,897196,999-4995,91885,42680,69079,86979,551-15626,650628,767625,580625,024599,920602,543598,908552,322551,621553,709536,577535,725534,911518,041514,413513,659512,910516,207490,766490,500489,357469,647464,445463,326461,829469,648460,073459,261458,959466,093456,901455,791405,805411,695363,299362,180361,102365,880357,287356,139355,020358,966356,436355,045353,772352,860331,859330,905330,369329,472270,979270,617270,209269,860223,398223,222223,031222,759222,116221,931221,7472,527000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue785
Cost of Revenue-0
Gross Profit785785
 
Operating Income (+$)
Gross Profit785
Operating Expense-42,499
Operating Income-41,714-41,714
 
Operating Expense (+$)
Research Development29,753
Selling General Administrative12,746
Selling And Marketing Expenses0
Operating Expense42,49942,499
 
Net Interest Income (+$)
Interest Income2,278
Interest Expense-0
Other Finance Cost-0
Net Interest Income2,278
 
Pretax Income (+$)
Operating Income-41,714
Net Interest Income2,278
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-39,479-43,949
EBIT - interestExpense = 0
-39,479
-39,479
Interest Expense0
Earnings Before Interest and Taxes (EBIT)0-39,479
Earnings Before Interest and Taxes (EBITDA)-41,714
 
After tax Income (+$)
Income Before Tax-39,479
Tax Provision-0
Net Income From Continuing Ops-41,715-39,479
Net Income-39,479
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses42,499
Total Other Income/Expenses Net2,235-2,278
 

Technical Analysis of Oncternal
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Oncternal. The general trend of Oncternal is BULLISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Oncternal's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (28.6%) Bearish trend (-28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Oncternal Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 9.48 < 9.852 < 10.40.

The bearish price targets are: 8.1786 > 7.4819 > 6.68.

Tweet this
Oncternal Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Oncternal Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 9/14.
The longshort score for the Moving Averages is 4/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Oncternal Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Oncternal Therapeutics Inc. The current macd is -0.0327226.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Oncternal price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Oncternal. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Oncternal price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Oncternal Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartOncternal Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Oncternal Therapeutics Inc. The current adx is 10.71.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Oncternal shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Oncternal Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Oncternal Therapeutics Inc. The current sar is 9.40532284.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Oncternal Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Oncternal Therapeutics Inc. The current rsi is 46.96. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
Oncternal Therapeutics Inc Daily Relative Strength Index (RSI) ChartOncternal Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Oncternal Therapeutics Inc. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Oncternal price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Oncternal Therapeutics Inc Daily Stochastic Oscillator ChartOncternal Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Oncternal Therapeutics Inc. The current cci is -72.90846522.

Oncternal Therapeutics Inc Daily Commodity Channel Index (CCI) ChartOncternal Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Oncternal Therapeutics Inc. The current cmo is -9.25846378.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Oncternal Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartOncternal Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Oncternal Therapeutics Inc. The current willr is -69.32087782.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Oncternal is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Oncternal Therapeutics Inc Daily Williams %R ChartOncternal Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Oncternal Therapeutics Inc.

Oncternal Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Oncternal Therapeutics Inc. The current atr is 0.56649529.

Oncternal Therapeutics Inc Daily Average True Range (ATR) ChartOncternal Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Oncternal Therapeutics Inc. The current obv is 509,886.

Oncternal Therapeutics Inc Daily On-Balance Volume (OBV) ChartOncternal Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Oncternal Therapeutics Inc. The current mfi is 51.76.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Oncternal Therapeutics Inc Daily Money Flow Index (MFI) ChartOncternal Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Oncternal Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-01STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-12MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-18CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-21WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-22MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-27RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-15WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-23CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-14CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-10DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-24STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Oncternal Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Oncternal Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.962
Ma 20Greater thanMa 508.832
Ma 50Greater thanMa 1008.884
Ma 100Greater thanMa 2008.810
OpenGreater thanClose8.780
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Oncternal with someone you think should read this too:
  • Are you bullish or bearish on Oncternal? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Oncternal? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Oncternal Therapeutics Inc

I send you an email if I find something interesting about Oncternal Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Oncternal Therapeutics Inc.

Receive notifications about Oncternal Therapeutics Inc in your mailbox!